On 24 August 2018, the Board of Directors of Asarina Pharma AB (publ) (“Asarina Pharma” or the “Company”), resolved, with the authorization from the Extraordinary General Meeting on 28 June, 2018, on a share issue of up to 6,800,000 shares (the “Offer”) and to apply for admission to trading of the Company’s share on Nasdaq First North. First day of trading is scheduled for September 24, 2018. The interest in participating in the Offer has been strong and the Offer was subscribed to approximately 275 percent. [...]